Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy
暂无分享,去创建一个
Anthony R Cillo | Ronald J Bosch | J. Mellors | J. Coffin | R. Bosch | M. Piatak | John M Coffin | A. Cillo | Michael Piatak | John W Mellors | Elizabeth Fyne | Michele D Sobolewski | Elizabeth Fyne | M. Sobolewski
[1] R. Lempicki,et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] E. Leifer,et al. Multiple Outputation: Inference for Complex Clustered Data by Averaging Analyses from Independent Data , 2003, Biometrics.
[3] Alberto Bosque,et al. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. , 2009, Blood.
[4] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[5] Frederic D. Bushman,et al. Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing , 2012, Nucleic acids research.
[6] L. McQuay,et al. Dilution assay statistics , 1994, Journal of clinical microbiology.
[7] C. Van Lint,et al. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. , 1993, The EMBO journal.
[8] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[9] T. Chun,et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. , 2012, The Journal of infectious diseases.
[10] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[11] J. Eron,et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.
[12] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[13] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[14] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[15] S. Kreth,et al. Selection of reliable reference genes for quantitative real-time PCR in human T cells and neutrophils , 2011, BMC Research Notes.
[16] D. Cooper,et al. Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection , 2012, PloS one.
[17] E. Verdin,et al. NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.
[18] T. Mahmoudi,et al. Repressive LTR Nucleosome Positioning by the BAF Complex Is Required for HIV Latency , 2011, PLoS biology.
[19] G. Boucher,et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton , 2010, Proceedings of the National Academy of Sciences.
[20] M. Mathews,et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.
[21] Amy S. Espeseth,et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. , 2009, AIDS research and human retroviruses.
[22] C. Mathis,et al. Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. , 2008, The American journal of pathology.
[23] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[24] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[25] R. Siliciano,et al. Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells , 2006, PLoS pathogens.
[26] Joseph A Kovacs,et al. ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.
[27] J. Mellors,et al. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] A. Krishnan,et al. Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma , 2013, Journal of acquired immune deficiency syndromes.
[29] John W. Mellors,et al. No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy , 2012, Journal of acquired immune deficiency syndromes.
[30] Tina Lenasi,et al. HMBA Releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and Activates HIV Transcription , 2007, PLoS pathogens.
[31] Jialing Huang,et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes , 2007, Nature Medicine.